Seegene Discusses Strengthening Business Cooperation with Catalonia, Spain

Establishment of a Technology-Sharing Joint Venture in Catalonia

Seegene, a total molecular diagnostics solutions company, announced on June 2 that CEO Cheon Jongyun and Salvador Illa Roca, Governor of Catalonia, Spain, have begun discussions to strengthen business cooperation.

Cheon Jongyun, CEO of Seegene (left), and Salvador Illa, Governor of Catalonia, Spain, are posing for a commemorative photo at Seegene headquarters in Songpa-gu, Seoul, on the 30th of last month. Seegene

On May 30, Governor Salvador Illa visited Seegene's headquarters in Songpa-gu, Seoul, where he met with CEO Cheon and expressed his support for Seegene's ongoing investment in Catalonia and his commitment to enhancing business collaboration. He stated, "I am well aware of Seegene's achievements during the COVID-19 pandemic," and added, "Catalonia aims to shift its healthcare system from reactive to preventive measures, and we will actively support efforts to overcome global health crises through Seegene's innovative technology."

CEO Cheon also commented, "Spain is a leading in vitro diagnostics (IVD) market in Europe, and Seegene has long been active there, establishing unique diagnostic systems through local partnerships," adding, "We will continue to pursue collaborative models such as technology-sharing projects to realize a 'world without disease.'"

Previously, on May 27, Seegene established "Werfen-Seegene," a technology-sharing joint venture with Werfen, Spain's top diagnostics company, in Catalonia. The Werfen-Seegene joint venture will jointly develop infectious disease diagnostic products optimized for the Spanish market based on Seegene's syndromic quantitative PCR technology and its automated reagent development system (SGDDS). It is also expected to serve as a strategic base for expanding into the European and global markets.

Seegene's syndromic quantitative PCR technology can test for up to 14 pathogens that cause similar symptoms in a single tube. When panel tests are performed using multiple tubes, it is possible to detect dozens of major pathogens, enabling the identification of multiple infections as well as providing quantitative information.

Seegene also introduced the current status of its technology-sharing business and its next-generation diagnostic system, CURECA, which is currently under development, to Governor Salvador Illa.

The technology-sharing business aims to share Seegene's diagnostic and data analysis technologies with leading companies in various countries, enabling experts to directly develop locally customized diagnostic products in a wide range of fields.

CURECA is Seegene's next-generation diagnostic system, which enables fully automated PCR testing without any human intervention. Designed as a modular device, it allows for customized configurations. It is expected to enable large-scale, unmanned testing 24 hours a day in laboratories, regardless of equipment operating hours or laboratory staff working hours.